Suppr超能文献

硫化氢可独立于血管紧张素转换酶抑制作用而产生外周血管效应。

Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition.

机构信息

Department of Pharmacy, University of Naples 'Federico II', Via D. Montesano 49, Naples 80131, Italy.

出版信息

Cardiovasc Res. 2014 Apr 1;102(1):138-47. doi: 10.1093/cvr/cvu026. Epub 2014 Feb 5.

Abstract

AIMS

Therapeutic use of sulfhydrylated inhibitor S-zofenopril has raised different hypotheses regarding the role played by its thiol group in the beneficial clinical effects exerted compared with other angiotensin-converting enzyme (ACE) inhibitors. Here, we investigated hydrogen sulfide (H2S) pathway as accountable for extra-beneficial effects in vascular function.

METHODS AND RESULTS

Spontaneously hypertensive rat (SHRs) and control Wistar Kyoto (WKY) rats were treated with either S-zofenopril or enalapril in vivo. Aorta and carotid were harvested and ex vivo vascular reactivity to acetylcholine (Ach) and L-cysteine (L-cys) assessed. Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptosulfur-transferase (3MST) expression, as well as H2S levels, were evaluated in both vascular tissues. The vascular response to Ach in both carotid and aorta was impaired in SHR (~30%, P < 0.001). S-zofenopril, but not enalapril, restored this response, while L-cys-induced relaxation was enhanced. CSE expression in vessels and tissue/plasma H2S levels were restored to WKY values in SHRs receiving S-zofenopril. In contrast, CBS and 3MST expression were not modified by treatments. S-zofenoprilat, an active metabolite of S-zofenopril, releases H2S in a 'cell-free' assay and it directly relaxed vessels in vitro in a concentration-dependent manner (P < 0.001). In vivo administration of R-zofenoprilat diasteroisomer, which does not inhibit ACE, did not modify blood pressure; nonetheless, it retained the beneficial effect on SHR vascular function as well as restored plasma/tissue H2S levels.

CONCLUSION

Our findings establish that S-zofenopril improves vascular function by potentiating the H2S pathway in a model of spontaneous hypertension. This novel mechanism, unrelated to ACE inhibition and based on H2S release, could explain the beneficial effects of sulfhydrylated ACE inhibitors reported in the clinical literature.

摘要

目的

巯基化抑制剂 S-佐芬普利的治疗用途引发了不同的假说,即其硫醇基团在与其他血管紧张素转换酶(ACE)抑制剂相比所产生的有益临床效果中发挥作用。在这里,我们研究了硫化氢(H2S)途径是否是血管功能的额外有益作用的原因。

方法和结果

体内给予自发性高血压大鼠(SHRs)和对照 Wistar Kyoto(WKY)大鼠 S-佐芬普利或依那普利。收获主动脉和颈动脉,并评估乙酰胆碱(Ach)和 L-半胱氨酸(L-cys)的体外血管反应。评估两种血管组织中的胱硫醚-β-合酶(CBS)、胱硫醚-γ-裂解酶(CSE)和 3-巯基转移酶(3MST)表达以及 H2S 水平。在颈动脉和主动脉中,Ach 的血管反应在 SHR 中受损(~30%,P < 0.001)。S-佐芬普利而非依那普利恢复了这种反应,而 L-cys 诱导的松弛增强。接受 S-佐芬普利的 SHR 中,血管和组织/血浆 H2S 水平的 CSE 表达恢复到 WKY 值。相比之下,CBS 和 3MST 表达不受治疗影响。S-佐芬普利的活性代谢物 S-佐芬普利拉在“无细胞”测定中释放 H2S,并以浓度依赖的方式直接在体外松弛血管(P < 0.001)。体内给予不抑制 ACE 的 R-佐芬普利拉差向异构体不会改变血压;然而,它保留了对 SHR 血管功能的有益作用,并恢复了血浆/组织 H2S 水平。

结论

我们的研究结果表明,S-佐芬普利通过增强自发性高血压模型中的 H2S 途径来改善血管功能。这种新的机制与 ACE 抑制无关,基于 H2S 的释放,可能解释了临床文献中报道的巯基化 ACE 抑制剂的有益作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验